Effect of angiotensinII type2 receptor on stroke, cognitive impairment and neurodegenerative diseases

Geriatrics and Gerontology International

Volumn 13, Issue 1, 2013, Pages 13-18

  Mogi, Masaki ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

AngiotensinII; AngiotensinII type2 receptor; Cerebral blood flow; Cerebrospinal fluid; Cognitive impairment; Stroke

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; CANDESARTAN; MITOGEN ACTIVATED PROTEIN KINASE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN DAMAGE; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN PROTECTION; CAUSE OF DEATH; CELL DIFFERENTIATION; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG PENETRATION; EXPERIMENTAL STUDY; HEMATOPOIESIS; HUMAN; HYPERTENSION; MICROENVIRONMENT; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION INJURY; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; BRAIN CIRCULATION; BRAIN LEVEL; DRUG EFFECT; DRUG POTENTIATION; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRAIN CHEMISTRY; CELL DIFFERENTIATION; CEREBROVASCULAR CIRCULATION; COGNITION DISORDERS; HUMANS; MICE; NEURODEGENERATIVE DISEASES; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; STROKE;

MLCS; MLOWN;

EID: 84871994373     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2012.00900.x     Document Type: Review

References (60)

1. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensinII receptors. Pharmacol Rev 2000; 52: 415-472.
2. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803.
3. Inaba S, Iwai M, Tomono Y etal. Exaggeration of focal cerebral ischemia in transgenic mice carrying human renin and human angiotensinogen genes. Stroke 2009; 40: 597-603.
4. Hosomi N, Mizushige K, Kitadai M etal. Induced hypertension treatment to improve cerebral ischemic injury after transient forebrain ischemia. Brain Res 1999; 835: 188-196.
5. Hosomi N, Nishiyama A, Ban CR etal. Angiotensin type1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 2005; 134: 225-231.
6. Schrader J, Luders S, Kulschewski A etal. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-1226.
7. Mochizuki S, Dahlof B, Shimizu M etal. Valsartan in a Japanese population with hypertension and other cardiovascular disease (JIKEI Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431-1439.
8. Sawada T, Yamada H, Dahlof B, Matsubara H. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: Kyoto Heart Study. Eur Heart J 2009; 30: 2461-2469.
9. Pelisch N, Hosomi N, Ueno M etal. Systemic candesartan reduces brain angiotensinII via downregulation of brain renin-angiotensin system. Hypertens Res 2010; 33: 161-164.
10. Mogi M, Horiuchi M. Remote control of brain angiotensinII levels by angiotensin receptor blockers. Hypertens Res 2010; 33: 116-117.
11. Iwai M, Liu HW, Chen R etal. Possible inhibition of focal cerebral ischemia by angiotensinII type2 receptor stimulation. Circulation 2004; 110: 843-848.
12. Iwai M, Chen R, Ide A etal. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of at1 receptor blockade on ischemic brain damage. J Hypertens 2006; 24: 2023-2031.
13. Iwai M, Inaba S, Tomono Y etal. Attenuation of focal brain ischemia by telmisartan, an angiotensinII type1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. Hypertens Res 2008; 31: 161-168.
14. Tsukuda K, Mogi M, Iwanami J etal. Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond at receptor blockade. Biochem Biophys Res Commun 2011; 409: 275-279.
15. Hamai M, Iwai M, Ide A etal. Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress. Neuropharmacology 2006; 51: 822-828.
16. Ovbiagele B, Kidwell CS, Starkman S etal. Angiotensin 2 type2 receptor activity and ischemic stroke severity. Neurology 2005; 65: 851-854.
17. Julius S, Nesbitt SD, Egan BM etal. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-1697.
18. Li JM, Mogi M, Iwanami J etal. Temporary pretreatment with the angiotensinII type1 receptor blocker, valsartan, prevents ischemic brain damage through an increase in capillary density. Stroke 2008; 39: 2029-2036.
19. Reinecke K, Lucius R, Reinecke A, Rickert U, Herdegen T, Unger T. AngiotensinII accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kappaB. FASEB J 2003; 17: 2094-2096.
20. Li J, Culman J, Hortnagl H etal. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19: 617-619.
21. Gendron L, Laflamme L, Rivard N, Asselin C, Payet MD, Gallo-Payet N. Signals from the AT2 (angiotensin type2) receptor of angiotensinII inhibit p21ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells. Mol Endocrinol 1999; 13: 1615-1626.
22. Cote F, Laflamme L, Payet MD, Gallo-Payet N. Nitric oxide, a new second messenger involved in the action of angiotensinII on neuronal differentiation of NG108-15 cells. Endocr Res 1998; 24: 403-407.
23. Cote F, Do TH, Laflamme L, Gallo JM, Gallo-Payet N. Activation of the AT(2) receptor of angiotensinII induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J Biol Chem 1999; 274: 31686-31692.
24. Li JM, Mogi M, Tsukuda K etal. AngiotensinII-induced neural differentiation via angiotensinII type2 (AT2) receptor-MMS2 cascade involving interaction between AT2 receptor-interacting protein and Src homology 2 domain-containing protein-tyrosine phosphatase 1. Mol Endocrinol 2007; 21: 499-511.
25. Zhang ZG, Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol 2009; 8: 491-500.
26. Li Y, Chen J, Wang L, Lu M, Chopp M. Treatment of stroke in rat with intracarotid administration of marrow stromal cells. Neurology 2001; 56: 1666-1672.
27. Li Y, Chen J, Chen XG etal. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 2002; 59: 514-523.
28. Li Y, Chopp M, Chen J etal. Intrastriatal transplantation of bone marrow nonhematopoietic cells improves functional recovery after stroke in adult mice. J Cereb Blood Flow Metab 2000; 20: 1311-1319.
29. Rempe DA, Kent TA. Using bone marrow stromal cells for treatment of stroke. Neurology 2002; 59: 486-487.
30. Strawn WB, Richmond RS, Ann Tallant E, Gallagher PE, Ferrario CM. Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol 2004; 126: 120-126.
31. Iwanami J, Mogi M, Li JM etal. Deletion of angiotensinII type2 receptor attenuates protective effects of bone marrow stromal cell treatment on ischemia-reperfusion brain injury in mice. Stroke 2008; 39: 2554-2559.
32. Iwanami J, Mogi M, Tsukuda K etal. Effect of angiotensinII type2 receptor deletion in hematopoietic cells on brain ischemia-reperfusion injury. Hypertension 2011; 58: 404-409.
33. Li NC, Lee A, Whitmer RA etal. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.
34. Chalmers J, MacMahon S. Perindopril protection against recurrent stroke study (PROGRESS): interpretation and implementation. J Hypertens Suppl 2003; 21: S9-14.
35. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
36. Ohrui T, Matsui T, Yamaya M etal. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 2004; 52: 649-650.
37. Ohrui T, Matsui T, Yamaya M, Kubo H, Arai H, Sasaki H. A new therapy for Alzheimer's disease. Geriatr Gerontol Int 2004; 4: 123-125.
38. Ohrui T, Tomita N, Sato-Nakagawa T etal. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324-1325.
39. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007; 6: 373-378.
40. Yamada K, Horita T, Takayama M etal. Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats. Brain Res 2011; 1421: 110-120.
41. Dong YF, Kataoka K, Tokutomi Y etal. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J 2011; 25: 2911-2920.
42. Yamada K, Uchida S, Takahashi S etal. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Brain Res 2010; 1352: 176-186.
43. Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005; 280: 37644-37650.
44. Zou K, Maeda T, Watanabe A etal. Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme. J Biol Chem 2009; 284: 31914-31920.
45. Mogi M, Li JM, Iwanami J etal. AngiotensinII type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006; 48: 141-148.
46. Wan Y, Wallinder C, Plouffe B etal. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 2004; 47: 5995-6008.
47. Jing F, Mogi M, Sakata A etal. Direct stimulation of angiotensinII type2 receptor enhances spatial memory. J Cereb Blood Flow Metab 2012; 32: 248-255.
48. Johren O, Dendorfer A, Dominiak P. Cardiovascular and renal function of angiotensinII type-2 receptors. Cardiovasc Res 2004; 62: 460-467.
49. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 2010; 120: 287-296.
50. Ge J, Barnes NM. Alterations in angiotensin at1 and AT2 receptor subtypelevels in brain regions from patients with neurodegenerative disorders. Eur J Pharmacol 1996; 297: 299-306.
51. Wosik K, Cayrol R, Dodelet-Devillers A etal. AngiotensinII controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 2007; 27: 9032-9042.
52. Stegbauer J, Lee DH, Seubert S etal. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A 2009; 106: 14942-14947.
53. Reardon KA, Mendelsohn FA, Chai SY, Horne MK. The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease. Aust N Z J Med 2000; 30: 48-53.
54. Iwasaki Y, Ichikawa Y, Igarashi O etal. Temocapril prevents motor neuron damage and upregulation of cyclooxygenase-II in glutamate-induced neurotoxicity. Neurol Res 2003; 25: 301-304.
55. Kawajiri M, Mogi M, Osoegawa M etal. Reduction of angiotensinII in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler 2008; 14: 557-560.
56. Kawajiri M, Mogi M, Higaki N etal. Reduced angiotensinII levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2009; 119: 341-344.
57. Gallagher PE, Chappell MC, Ferrario CM, Tallant EA. Distinct roles for ang II and ang-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol 2006; 290: C420-C426.
58. Kawajiri M, Mogi M, Higaki N etal. Angiotensin-converting enzyme (ACE) and ACE2 levels in the cerebrospinal fluid of patients with multiple sclerosis. Mult Scler 2009; 15: 262-265.
59. Lanz TV, Ding Z, Ho PP etal. AngiotensinII sustains brain inflammation in mice via tgf-beta. J Clin Invest 2010; 120: 2782-2794.
60. Liu G, Hosomi N, Hitomi H etal. AngiotensinII induces human astrocyte senescence through reactive oxygen species production. Hypertens Res 2011; 34: 479-483.